Safinamide has received FDA approval as an add-on treatment for patients with Parkinson disease who take levodopa and carbidopa but have “off” episodes, when medication doesn’t adequately control symptoms such as tremor.
More than 1 million people in North America have Parkinson disease; about 60 000 new cases are diagnosed in the United States each year. “Parkinson’s is a relentless disease without a cure,” Eric Bastings, MD, deputy director of the FDA’s Division of Neurology Products, said in a statement.
Voelker R. New Addition to Parkinson Therapy. JAMA. 2017;317(17):1716. doi:10.1001/jama.2017.4468
Customize your JAMA Network experience by selecting one or more topics from the list below.